I've been posting informative bullet points on IDRA for 2 years now. Sometimes, a lttle pie in the sky fun. What's wrong with that? GLTU
Ivan owns 2.3m shares of his own company. FMR 11%. Goldman. Tia-crep. And on. CRs already reported with detail promised this year. Will pop fast.
Good point. I keep forgetting about the #$%$-for-brains around obama. Still, I'll buy more of this and STML at these levels.
Rate hike December push-out due to market fragile. Should see a charge in the afternoon, starting with fundamentally sound stocks that have been blasted by market forces alone.
Agree. Waited patiently for 2s again --- the 2s that no one believed would be here again just 3 weeks ago. This is where the greedy pigs take out the retail with fear, as you can clearly see with those million-dollar purchases end of day last several days. Here is what's coming, starting AACR:
1. NEW data on 2125 kicking melanoma's #$%$ in tandem.
2. Dermo launch Ph2
3. 3gA targets that have been CARFULLY selected for fastest to market, unmet needs, and CLEAR, INDISPUTABLE endpoints.
4. WM at ASH. ONE GENE. All patients have tried everything else. IDRA believes so strongly in their research that they paid out millions for a companion diagnostic AND started up DLBCL. Not a normal thing to do without first seeing WM results. Agrawal knows. Goldman knows. JPM knows. Bakers know. Fidelity knows. Geraghty knows. Milano knows. All of these parties are in at a price 30% above these levels, and they are not in for a 30-cent gain and a whimsical guess.
From mid September AACR through next year and beyond, there are catalysts one after another. Ph3 WM and DLBCL end of 2017 latest, and 3gA Ph2 same. We're looking at a 10 bagger. All you need is patience and follow the money.